310 related articles for article (PubMed ID: 23763511)
1. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
Morizane C; Okusaka T; Mizusawa J; Takashima A; Ueno M; Ikeda M; Hamamoto Y; Ishii H; Boku N; Furuse J
Cancer Sci; 2013 Sep; 104(9):1211-6. PubMed ID: 23763511
[TBL] [Abstract][Full Text] [Related]
2. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
[TBL] [Abstract][Full Text] [Related]
7. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Ito Y; Yasuda I; Toda N; Kogure H; Hanada K; Maguchi H; Sasahira N; Kamada H; Mukai T; Okabe Y; Hasebe O; Maetani I; Koike K
Cancer Chemother Pharmacol; 2013 Apr; 71(4):973-9. PubMed ID: 23355041
[TBL] [Abstract][Full Text] [Related]
10. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
[TBL] [Abstract][Full Text] [Related]
12. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Sakai D; Kodama Y; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2012 May; 69(5):1181-8. PubMed ID: 22237958
[TBL] [Abstract][Full Text] [Related]
17. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
[No Abstract] [Full Text] [Related]
18. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
[TBL] [Abstract][Full Text] [Related]
19. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Ito Y; Kogure H; Togawa O; Toda N; Yasuda I; Hasebe O; Maetani I; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M
Cancer Chemother Pharmacol; 2010 May; 65(6):1101-7. PubMed ID: 19707761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]